Renalytix PLC
LSE:RENX
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
Dell Technologies Inc
NYSE:DELL
|
Technology
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Abercrombie & Fitch Co
NYSE:ANF
|
Retail
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
S&P Global Inc
NYSE:SPGI
|
Financial Services
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
| US |
|
Citigroup Inc
NYSE:C
|
Banking
|
| IE |
|
Iterum Therapeutics PLC
NASDAQ:ITRM
|
Pharmaceuticals
|
| US |
|
Medpace Holdings Inc
NASDAQ:MEDP
|
Life Sciences Tools & Services
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
7.5
50.4
|
| Price Target |
|
We'll email you a reminder when the closing price reaches GBX.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
Dell Technologies Inc
NYSE:DELL
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Abercrombie & Fitch Co
NYSE:ANF
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
S&P Global Inc
NYSE:SPGI
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Walt Disney Co
NYSE:DIS
|
US |
|
|
Citigroup Inc
NYSE:C
|
US |
|
|
Iterum Therapeutics PLC
NASDAQ:ITRM
|
IE |
|
|
Medpace Holdings Inc
NASDAQ:MEDP
|
US |
This alert will be permanently deleted.
Renalytix PLC
Renalytix PLC
Intangible Assets
Renalytix PLC
Intangible Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Intangible Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Renalytix PLC
LSE:RENX
|
Intangible Assets
$12.5m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Craneware PLC
LSE:CRW
|
Intangible Assets
$202.2m
|
CAGR 3-Years
67%
|
CAGR 5-Years
46%
|
CAGR 10-Years
30%
|
|
|
Cambridge Cognition Holdings PLC
LSE:COG
|
Intangible Assets
£3.7m
|
CAGR 3-Years
115%
|
CAGR 5-Years
56%
|
CAGR 10-Years
N/A
|
|
|
Intelligent Ultrasound Group PLC
LSE:IUG
|
Intangible Assets
£4.1m
|
CAGR 3-Years
28%
|
CAGR 5-Years
7%
|
CAGR 10-Years
N/A
|
|
|
EMIS Group PLC
LSE:EMIS
|
Intangible Assets
£35.5m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
1%
|
|
|
Doctor Care Anywhere Group PLC
ASX:DOC
|
Intangible Assets
£6m
|
CAGR 3-Years
19%
|
CAGR 5-Years
19%
|
CAGR 10-Years
N/A
|
|
Renalytix PLC
Glance View
Renalytix Plc manufactures medical devices and equipment. The company is headquartered in Penarth, South Glamorgan. The company went IPO on 2018-11-06. The firm is focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care. The firm's diagnostic platform, KidneyIntelX, is designed to scale across kidney disease conditions beyond diabetic kidney disease. The firm is evaluating a range of new indications in chronic kidney disease, cardio-renal disease, chronic kidney disease in diverse populations and coronavirus disease (COVID)-related kidney disease. KidneyIntelX platform facilitates the identification and promotes the effective management of patients at risk of early-stage diabetic kidney disease (DKD), progression by combining diverse data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record (HER) using a proprietary algorithm to generate a unique patient risk score.
See Also
What is Renalytix PLC's Intangible Assets?
Intangible Assets
12.5m
USD
Based on the financial report for Jun 30, 2023, Renalytix PLC's Intangible Assets amounts to 12.5m USD.
What is Renalytix PLC's Intangible Assets growth rate?
Intangible Assets CAGR 3Y
-10%
Over the last year, the Intangible Assets growth was -11%. The average annual Intangible Assets growth rates for Renalytix PLC have been -10% over the past three years .
You don't have any saved screeners yet
